Noriyuki Masuda

Izumi City General Hospital — Japan

Medicine · Health Sciences

31h-index3.8kcitations247works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(73), Lung Cancer Treatments and Mutations(70), Neuroendocrine Tumor Research Advances(31), Cancer therapeutics and mechanisms(29), Lung Cancer Diagnosis and Treatment(25)

Publications247 total

PD-1/PD-L1 checkpoint inhibitor-induced encephalitis in patients with lung adenocarcinoma: a report of three cases
Oxford Medical Case Reports·2025Open Access
Bioequivalence Study of Erlotinib Tablets 25 mg/150 mg “NK” in Healthy Male Volunteers with an Adaptive Design
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics·2024
Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers
Vaccine·2022· 4 citedOpen Access
Muscarinic <scp>M<sub>3</sub></scp> positive allosteric modulator <scp>ASP8302</scp> enhances bladder contraction and improves voiding dysfunction in rats
LUTS Lower Urinary Tract Symptoms·2022· 2 cited
Potentiation of Muscarinic M3 Receptor Activation through a New Allosteric Site with a Novel Positive Allosteric Modulator ASP8302
Journal of Pharmacology and Experimental Therapeutics·2021· 9 citedOpen Access
Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer
Clinical Lung Cancer·2020· 6 citedOpen Access
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)
Investigational New Drugs·2020
Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503
Lung Cancer·2019· 11 cited
Prognostic significance of IMMT expression in surgically‐resected lung adenocarcinoma
Thoracic Cancer·2019· 10 citedOpen Access
Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
Internal Medicine·2019· 9 citedOpen Access
Modulation of urinary frequency via type 1 lysophosphatidic acid receptors: Effect of the novel antagonist ASP6432 in conscious rats
European Journal of Pharmacology·2019· 1 cited
Effect of ASP2205 fumarate, a novel 5-HT2C receptor agonist, on urethral closure function in rats
Journal of Pharmacological Sciences·2019· 5 citedOpen Access
Safety and effectiveness of alectinib in a real‐world surveillance study in patients with <i><scp>ALK</scp></i>‐positive non–small‐cell lung cancer in Japan
Cancer Science·2019· 31 citedOpen Access
ASP6432, a type 1 lysophosphatidic acid receptor antagonist, reduces urethral function during urine voiding and improves voiding dysfunction
European Journal of Pharmacology·2019· 6 cited
Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib
Journal of Thoracic Oncology·2018· 48 citedOpen Access
How should we exploit TAS-102?
Annals of Oncology·2018· 1 citedOpen Access
Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation
Journal of Pharmacology and Experimental Therapeutics·2018· 7 citedOpen Access
Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
Internal Medicine·2018· 1 citedOpen Access
A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
BMJ Case Reports·2018· 4 citedOpen Access
MP09-01 EFFECT OF ASP6432, A TYPE 1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST, ON URETHRAL FUNCTION DURING THE VOIDING PHASE IN RATS
The Journal of Urology·2018Open Access
page 1 of 13Next →

Frequent Co-authors

Shinichiro Ryuge(17), Yuichi Sato(15), Yukitoshi Satoh(14), Masahiro Fukuoka(12), Ryo Nagashio(12), Ken Katono(11), Makoto Saegusa(9), Makoto Kobayashi(8), Shi-Xu Jiang(7), Shunichi Negoro(6), Shi‐Xu Jiang(6), Toshihide Matsumoto(6), Satoshi Igawa(6), Kazuhiko Nakagawa(5), Shinzoh Kudoh(5), Kenji Eguchi(4), Tomoya Fukui(4), Masato Katagiri(4), Taihei Kageyama(4), Naoki Goshima(4)